Reference : Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosi...
Scientific congresses and symposiums : Paper published in a journal
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/174031
Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial
English
McClung, MR []
Langdahl, B []
Papapoulos, S []
Saag, KG []
Adami, S []
Bone, HG []
de Villiers, T []
Kiel, DP []
Kung, A []
Kumar, P []
Lim, SK []
Ling, X []
Lippuner, K []
Mautalen, C []
Nakamura, T []
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Reid, IR []
Rodriguez-Portales, JA []
Roux, C []
Walliser, J []
Watts, NB []
Zanchetta, J []
Zerbini, CA []
Rybak-Feiglin, A []
Cohn, D []
DaSilva, CA []
Massaad, R []
Santora, A []
Scott, BB []
Verbruggen, N []
Leung, A []
Lombardi, A []
2014
Osteoporosis International
Springer Science & Business Media B.V.
25
5
573-575
Yes (verified by ORBi)
International
0937-941X
1433-2965
Godalming
United Kingdom
IOF 5th Asia Pacif Osteoporosis Meeting
Du 14 novembre 2014 au 16 novembre 2014
Taipei
Taiwan, Province of China
http://hdl.handle.net/2268/174031

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis results from the phase III long-term odanacatib fracture trial.pdfPublisher postprint325.49 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.